Fate Therapeutics Inc FATE:NASDAQ

Last Price$37.80NASDAQ Previous Close - Last Trade as of 3:59PM ET 9/25/20

Today's Change+1.81(5.03%)
Bid (Size)$37.79 (27)
Ask (Size)$37.80 (1)
Day Low / High$35.80 - 37.97
Volume629.4 K

View Biotechnology IndustryPeer Comparison as of 09/25/2020


Fate Therapeutics Inc ( NASDAQ )

Price: $37.80
Change: +1.81 (5.03%)
Volume: 629.4 K
3:59PM ET 9/25/2020

Twist Bioscience Corp ( NASDAQ )

Price: $72.64
Change: +6.15 (9.25%)
Volume: 490.4 K
3:59PM ET 9/25/2020

Global Blood Therapeutics Inc ( NASDAQ )

Price: $54.18
Change: +0.83 (1.56%)
Volume: 1.4 M
4:00PM ET 9/25/2020

PTC Therapeutics Inc ( NASDAQ )

Price: $46.60
Change: +0.22 (0.47%)
Volume: 524.4 K
4:00PM ET 9/25/2020

Insmed Inc ( NASDAQ )

Price: $33.61
Change: +0.15 (0.45%)
Volume: 746.3 K
3:59PM ET 9/25/2020

Read more news Recent News

Insider Trends: Fate Therapeutics Insider Sale Interrupting 90-Day Buy Trend
4:03PM ET 9/16/2020 MT Newswires

Daniel D Shoemaker, Chief Scientific Officer, sold 25,000 shares of Fate Therapeutics (FATE) on Sep 14, 2020, for $907,540. Subsequent to the Form 4...

Fate Therapeutics Names New Finance Chief
8:38AM ET 8/19/2020 MT Newswires

Fate Therapeutics (FATE) said Wednesday Edward Dulac has been appointed as its new finance chief. Dulac most recently served as vice president in Celgene's...

Analyst Actions: Cantor Fitzgerald Lifts Fate Therapeutics PT to $40 From $32, Maintains Overweight Rating
11:08AM ET 8/13/2020 MT Newswires

Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $37. (MT Newswires covers equity, commodity and economic...

Fate Therapeutics Q2 Results Miss Expectations
4:29PM ET 8/05/2020 MT Newswires

Fate Therapeutics (FATE) on Wednesday reported a Q2 loss per diluted share of $0.35, narrower than the loss of $0.36 a year ago. Revenue increased to $5.5...

Company Profile

Business DescriptionFate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. View company web site for more details
Address3535 General Atomics Court
San Diego, California 92121
Number of Employees104
Recent SEC Filing09/16/20204
President, Chief Executive Officer & DirectorJ. Scott Wolchko
Chief Financial Officer & Accounting OfficerEdward J. Dulac
Chief Scientific OfficerDaniel D. Shoemaker
Senior Vice President-Technical OperationsWen Bo Wang

Company Highlights

Price Open$35.80
Previous Close$35.99
52 Week Range$12.59 - 39.45
Market Capitalization$3.3 B
Shares Outstanding86.8 M
SectorHealth Technology
Next Earnings Announcement11/03/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.57
Beta vs. S&P 500N/A
Revenue$4.7 M
Net Profit Margin-881.86%
Return on Equity-38.64%

Analyst Ratings as of 05/12/2020

Consensus RecommendationConsensus Icon
Powered by Factset